International โ€บ Comparison ยท Last reviewed 2026-05-16

International comparison

Policy and current status of adolescent gender care in nine countries, in one overview. The last column links to the dossier where each row is substantiated.

CountryKey documentGnRHa < 18CSH < 18Required settingDossier
NetherlandsQuality Standard Transgender Care โ€“ Somatic (2019); Health Council advice (2026)PermittedPermitted from 15โ€“16 under conditionsClinical carecurrent status NL
UKCass Review 2024 + NHS England 2024Research onlyRestrictiveResearch / specialist hubsUK ยท Cass
SwedenSBU 2022 + Socialstyrelsen 2022Research setting or exceptional casesResearch setting or exceptional casesResearchSweden ยท SBU
FinlandCOHERE 2020Selective, psychotherapy firstSelectiveTwo specialised centresFinland ยท COHERE
NorwayUkom 2023 (recommendations)Recommended to be defined as experimental treatmentRecommended to be defined as experimental treatmentRevision of the national guideline recommendedNorway
DenmarkSundhedsstyrelsen guidance (2018)Possible from Tanner stage IIโ€“IIIFrom about age 15โ€“16National serviceDenmark
GermanyAWMF S2k guideline (registry no. 028-014)PermittedPermittedGuideline-based careGermany
US (federal)Endocrine Society 2017 + AAP 2018Permitted (varies by state)Permitted (varies by state)Clinical careUS
US (states with bans, e.g. Tennessee)State laws; Supreme Court, Skrmetti (18 June 2025)Prohibited where bans applyProhibited where bans applyn/aSkrmetti
AustraliaRCH Melbourne SoC 2018Varies by state (Queensland: paused)Varies by state (Queensland: paused)Clinical careAustralia

What the table shows

Two groups are recognisable: (a) countries where medical treatment of minors remains available within existing guidelines (Netherlands, Germany, part of the US) and (b) countries or states that have restricted it (UK, Sweden, Finland, Queensland, part of the US), while Norway's Ukom has recommended defining the treatment as experimental. Between 2020 and 2025 several of them tightened their policy: Finland (COHERE, June 2020), Sweden (Socialstyrelsen, 2022), the UK (NHS England, 2024) and Queensland (2025). The Dutch Health Council notes that in Germany, Austria, Switzerland, France and Poland treatment has recently been anchored more firmly in guidelines (source).

Critical note

Not every revision rests on the same kind of evidence review: Sweden (SBU 2022) and England (the York reviews for the Cass Review) had the evidence reviewed systematically, whereas Norway's Ukom noted that Norway has no systematic knowledge summary and recommended that one be made (source). In June 2026 the Dutch Health Council advised against changing Dutch care, while rating the strength of the evidence as "low to very low" and concluding that cognition, fertility and long-term effects are insufficiently studied (source).

See also